Literature DB >> 17376993

Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons.

Matthew P Mount1, Arman Lira, David Grimes, Patrice D Smith, Sylvie Faucher, Ruth Slack, Hymie Anisman, Shawn Hayley, David S Park.   

Abstract

Growing evidence implicates microglia in the loss of dopaminergic neurons in Parkinson's disease (PD). However, factors mediating microglial activation in PD are poorly understood. Proinflammatory cytokines, such as interferon-gamma (IFN-gamma), orchestrate the actions of microglia. We report here that PD patients express significantly elevated levels of IFN-gamma in their blood plasma. After this initial finding, we found that IFN-gamma-deficient mice displayed attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced substantia nigra pars compacta dopaminergic cell loss along with reduced loss of striatal tyrosine hydroxylase and dopamine transporter fiber density. MPTP-induced depletion of striatal dopamine and its metabolite DOPAC (3,4-dihydroxyphenylacetic acid), as well as deltaFosB, a marker of postsynaptic dysfunction, were also attenuated in these knock-out mice. Consistent with the role for IFN-gamma in microglial activation, MPTP-induced morphological activation of microglia was abrogated compared with wild-type mice. To examine more mechanistically the role of IFN-gamma in microglial activation, we evaluated the interactions between microglia and dopaminergic neurons in an in vitro mixed microglia/midbrain neuron rotenone-induced death paradigm. In this in vitro paradigm, dopaminergic neurons are selectively damaged by rotenone. Exogenous IFN-gamma ligand alone and without rotenone resulted in dopaminergic cell loss, but only in the presence of microglia. The addition of an IFN-gamma neutralizing antibody attenuated neuronal loss as a result of rotenone treatment. The presence of only wild-type microglia and not those deficient in IFN-gamma receptor elicited significant dopaminergic cell loss when exposed to rotenone. Neurons deficient in IFN-gamma receptor, however, did not display increased resistance to death. Finally, levels of IFN-gamma message increased in microglia in response to rotenone. Together, these data suggest that IFN-gamma participates in death of dopaminergic neurons by regulating microglial activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376993      PMCID: PMC6672486          DOI: 10.1523/JNEUROSCI.5321-06.2007

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  108 in total

1.  Real-time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy.

Authors:  V Rangroo Thrane; A S Thrane; J Chang; J Chanag; V Alleluia; E A Nagelhus; M Nedergaard
Journal:  Neuroscience       Date:  2012-06-21       Impact factor: 3.590

Review 2.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

Review 3.  Immune activation in brain aging and neurodegeneration: too much or too little?

Authors:  Kurt M Lucin; Tony Wyss-Coray
Journal:  Neuron       Date:  2009-10-15       Impact factor: 17.173

Review 4.  T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?

Authors:  Stanley H Appel; David R Beers; Jenny S Henkel
Journal:  Trends Immunol       Date:  2009-10-31       Impact factor: 16.687

5.  β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease.

Authors:  Shuchi Mittal; Kjetil Bjørnevik; Doo Soon Im; Adrian Flierl; Xianjun Dong; Joseph J Locascio; Kristine M Abo; Elizabeth Long; Ming Jin; Bing Xu; Yang K Xiang; Jean-Christophe Rochet; Anders Engeland; Patrizia Rizzu; Peter Heutink; Tim Bartels; Dennis J Selkoe; Barbara J Caldarone; Marcie A Glicksman; Vikram Khurana; Birgitt Schüle; David S Park; Trond Riise; Clemens R Scherzer
Journal:  Science       Date:  2017-09-01       Impact factor: 47.728

Review 6.  Parkinson's disease and enhanced inflammatory response.

Authors:  Iva Stojkovska; Brandon M Wagner; Brad E Morrison
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-13

Review 7.  Mechanism of Gene-Environment Interactions Driving Glial Activation in Parkinson's Diseases.

Authors:  Souvarish Sarkar
Journal:  Curr Environ Health Rep       Date:  2021-05-27

Review 8.  Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.

Authors:  Juan A Orellana; Pablo J Sáez; Kenji F Shoji; Kurt A Schalper; Nicolás Palacios-Prado; Victoria Velarde; Christian Giaume; Michael V L Bennett; Juan C Sáez
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

9.  Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Matthew P Mount; Yi Zhang; Mandana Amini; Steve Callaghan; Jerzy Kulczycki; Zixu Mao; Ruth S Slack; Hymie Anisman; David S Park
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

10.  Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  Kyota Fujita; Toshihiro Seike; Noriko Yutsudo; Mizuki Ohno; Hidetaka Yamada; Hiroo Yamaguchi; Kunihiko Sakumi; Yukiko Yamakawa; Mizuho A Kido; Atsushi Takaki; Toshihiko Katafuchi; Yoshinori Tanaka; Yusaku Nakabeppu; Mami Noda
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.